Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease
Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA
Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
Amgen wins European approval for Uplizna in generalised myasthenia gravis
Akeso's AK139 Phase II clinical trials approved in China
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals